Uto Kenta, Ota Yoshimi, Mizuno Masayuki, Nakamura Ayako, Nakajima Ritsuko, Endoh Yasuhiro, Kasanuki Hiroshi
Department of Cardiology, Saiseikai Kurihashi Hospital, Saitama.
J Cardiol. 2002 Dec;40(6):241-8.
To elucidate the effectiveness and safety of intravenous thrombolysis (IVT) with mutant tissue plasminogen activator prior to percutaneous coronary intervention (PCI) in patients with acute myocardial infarction.
Ninety consecutive patients were recruited with the following criteria: acute myocardial infarction with ST segment elevation or bundle branch block on electrocardiography, admission within 6 hr from onset, age of < or = 80 years and without previous PCI or coronary bypass graft surgery. They were divided into two groups. Group IV consisted of 53 patients treated with IVT prior to PCI and Group D consisted of the other 37 patients with direct PCI. Mutant tissue plasminogen activator, monteplase, was administered with a dose of 27,500 U/kg in Group IV (maximum injection dose, 160 x 10(4) U). The clinical features and in-hospital outcome were compared between the two groups.
Patients in Group IV acquired earlier reperfusion estimated by electrocardiography recovery at 60 min after admission and higher Thrombolysis in Myocardial Infaction (TIMI) flow grade on the first coronary angiogram (TIMI 2 or 3 flow rate; Group IV vs Group D = 75% vs 35%, p < 0.0001). The duration from onset to TIMI 3 flow grade was not significantly different between Group IV and Group D (230 vs 260 min, p = 0.15). The incident of ST segment re-elevation with chest pain at recanalization was lower in Group IV than in Group D (23% vs 46%, p < 0.05). The duration from TIMI 3 recognition to peak creatine kinase level was longer in Group IV (466 vs 359 min, p = 0.039). Subacute thrombotic occlusion occurred in two patients in Group IV and three in Group D (NS). One patient in each group died from pump failure (NS). No severe bleeding complication was found in any patient.
IVT prior to PCI was considered to be a safe, effective and useful therapy in patients with acute myocardial infarction. Different patterns of reperfusion might occur, because of the low frequency of ST re-elevation and elongation of duration from reperfusion to peak creatine kinase level in patients treated with IVT prior to PCI.
阐明在急性心肌梗死患者经皮冠状动脉介入治疗(PCI)前使用变异型组织纤溶酶原激活剂进行静脉溶栓(IVT)的有效性和安全性。
连续纳入90例符合以下标准的患者:心电图显示ST段抬高或束支传导阻滞的急性心肌梗死,发病6小时内入院,年龄≤80岁,且既往未行PCI或冠状动脉搭桥手术。他们被分为两组。IV组由53例在PCI前接受IVT治疗的患者组成,D组由另外37例直接接受PCI的患者组成。IV组使用变异型组织纤溶酶原激活剂蒙特普酶,剂量为27,500 U/kg(最大注射剂量160×10⁴ U)。比较两组的临床特征和院内结局。
IV组患者在入院60分钟时通过心电图恢复评估的再灌注更早,首次冠状动脉造影时心肌梗死溶栓(TIMI)血流分级更高(TIMI 2或3级血流;IV组与D组分别为75%对35%,p<0.0001)。IV组和D组从发病到TIMI 3级血流的持续时间无显著差异(230分钟对260分钟,p = 0.15)。IV组再灌注时伴有胸痛的ST段再次抬高发生率低于D组(23%对46%,p<0.05)。IV组从TIMI 3级血流确认到肌酸激酶峰值水平的持续时间更长(466分钟对359分钟,p = 0.039)。IV组有2例患者发生亚急性血栓闭塞,D组有3例(无显著差异)。每组各有1例患者死于泵衰竭(无显著差异)。未发现任何患者有严重出血并发症。
PCI前的IVT被认为是急性心肌梗死患者安全、有效且有用的治疗方法。由于PCI前接受IVT治疗的患者ST段再次抬高频率低以及从再灌注到肌酸激酶峰值水平的持续时间延长,可能会出现不同的再灌注模式。